Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 476 - 500 of 1286 in total

Alpha-1-proteinase inhibitor

Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
Approved
Matched Synonyms: … .-1 protease inhibitor ... Protease inhibitor wap4 ... Alpha-1 protease inhibitor …
Matched Name: … Alpha-1-proteinase inhibitor …
Matched Description: … Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol …
Matched Categories: … Human alpha-1 Proteinase Inhibitor …
Matched Products: … Alpha1-proteinase Inhibitor (human) …

Protein C

Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface...
Approved
Matched Synonyms: … Protein C (coagulation inhibitor) …

Mavorixafor

Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized by a reduced number of mature neutrophils and lymphocytes. WHIM syndrome is caused by...
Approved
Investigational
Matched Synonyms: … CXCR4 INHIBITOR X4P-001 …

Ibrexafungerp

Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection.[A235384,L34349] It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole...
Approved
Investigational
Matched Synonyms: … enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor …

Tofersen

Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS). Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented.[A259028,A259033] Tofersen was granted accelerated approval from the FDA...
Approved
Investigational
Matched Synonyms: … Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene …

Letrozole

Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
Approved
Investigational
Matched Description: … Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the ... [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole …
Matched Categories: … Aromatase Inhibitors …

Formestane

Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production from anabolic steroids or prohormones. Formestane is also a prohormone of 4-hydroxytestosterone, an active steroid with weak androgenic activity and mild aromatase inhibitor activity....
Approved
Investigational
Withdrawn
Matched Description: … With the discovery of newer, non-steroidal and steroidal, aromatase inhibitors which were orally active ... Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor ... inhibitor activity. …
Matched Categories: … Aromatase Inhibitors …

Factor IX Complex (Human)

Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of...
Approved
Investigational
Matched Mixtures name: … Feiba Vh Immuno Anti Inhibitor …

Coagulation factor X human

Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency. However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe...
Approved
Investigational
Matched Mixtures name: … Feiba Vh Immuno Anti Inhibitor …

Exemestane

Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Approved
Investigational
Matched Description: … Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive …
Matched Categories: … Aromatase Inhibitors …

Mafenide

Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. In 1998, mafenide acetate was approved under the FDA’s accelerated approval regulations. In November 2022, the use of mafenide acetate (powder...
Approved
Vet approved
Withdrawn

Aminoglutethimide

An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale,...
Approved
Investigational
Matched Description: … An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of …
Matched Categories: … Aromatase Inhibitors …

Gabapentin

Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic...
Approved
Investigational

Ravulizumab

Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking...
Approved
Investigational
Matched Description: … Ravulizumab is a potent and selective complement 5 (C5) inhibitor. ... [L39690] Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the …

Entecavir

Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS). Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents...
Approved
Investigational
Matched Categories: … Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor …

Ponatinib

Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Approved
Investigational
Matched Description: … Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I …
Matched Categories: … Kinase Inhibitor …

Trastuzumab deruxtecan

Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of...
Approved
Investigational
Matched Description: … Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved …

Lorlatinib

Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive...
Approved
Investigational
Matched Description: … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic …
Matched Categories: … Kinase Inhibitor …

Pibrentasvir

Pibrentasvir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS5A inhibitor that targets the the viral RNA replication and viron assembly. In combination with DB13879, pibrentastiv is a useful therapy for patients who experienced therapeutic failure from other NS5A inhibitors. In cell cultures, the emergence of amino...
Approved
Investigational
Matched Description: … or an NS3/4A protease inhibitor, but not both [L940]. ... Pibrentasvir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS5A inhibitor that targets ... In cell cultures, the emergence of amino acid substitutions at known NS5A inhibitor resistance-associated …
Matched Categories: … Hepatitis C Virus NS5A Inhibitor …

Glecaprevir

Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with DB13878, glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic barrier against resistance...
Approved
Investigational
Matched Description: … or an NS3/4A protease inhibitor, but not both [L940]. ... Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor ... genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor …

Lifileucel

Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.
Approved
Investigational

Elvitegravir

Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the...
Approved
Matched Description: … Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI ... Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor …
Matched Categories: … Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor …

Peginterferon alfa-2b

Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved

Anidulafungin

Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.
Approved
Investigational

Ciltacabtagene autoleucel

Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000, and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience a range of symptoms including...
Approved
Investigational
Displaying drugs 476 - 500 of 1286 in total